Terumo Corp ADR
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $21.77 billion
- Book Value:
- Revenue TTM:
- $838.12 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $417.37 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Terumo Corp ADR had its IPO on under the ticker symbol TRUMY.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Terumo Corp ADR has a staff strength of 30,207 employees.
Shares of Terumo Corp ADR opened at $29.29 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $29.16 - $29.36, and closed at $29.24.
This is a +1.46% increase from the previous day's closing price.
A total volume of 63,720 shares were traded at the close of the day’s session.
In the last one week, shares of Terumo Corp ADR have slipped by -3.18%.
Terumo Corp ADR's Key Ratios
Terumo Corp ADR has a market cap of $21.77 billion, indicating a price to book ratio of 2.5184 and a price to sales ratio of 0.0286.
In the last 12-months Terumo Corp ADR’s revenue was $838.12 billion with a gross profit of $417.37 billion and an EBITDA of $190.59 billion. The EBITDA ratio measures Terumo Corp ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Terumo Corp ADR’s operating margin was 14.2% while its return on assets stood at 4.57% with a return of equity of 7.72%.
In Q2, Terumo Corp ADR’s quarterly earnings growth was a positive 2.3% while revenue growth was a positive 9.1%.
Terumo Corp ADR’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.81 per share while it has a forward price to earnings multiple of 22.2222 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Terumo Corp ADR’s profitability.
Terumo Corp ADR stock is trading at a EV to sales ratio of 0.0287 and a EV to EBITDA ratio of 0.127. Its price to sales ratio in the trailing 12-months stood at 0.0286.
Terumo Corp ADR stock pays annual dividends of $40 per share, indicating a yield of 0.98% and a payout ratio of 33.17%.
Balance sheet and cash flow metrics
- Total Assets
- $1,670.80 billion
- Total Liabilities
- $339.37 billion
- Operating Cash Flow
- Capital Expenditure
- $19.11 billion
- Dividend Payout Ratio
Terumo Corp ADR ended 2023 with $1,670.80 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1,670.80 billion while shareholder equity stood at $1,202.66 billion.
Terumo Corp ADR ended 2023 with $0 in deferred long-term liabilities, $339.37 billion in other current liabilities, 38716000000.00 in common stock, $881.11 billion in retained earnings and $0 in goodwill. Its cash balance stood at $160.05 billion and cash and short-term investments were $179.16 billion. The company’s total short-term debt was $153,854,000,000 while long-term debt stood at $74.97 billion.
Terumo Corp ADR’s total current assets stands at $633.68 billion while long-term investments were $0 and short-term investments were $19.11 billion. Its net receivables were $160.58 billion compared to accounts payable of $85.51 billion and inventory worth $272.50 billion.
In 2023, Terumo Corp ADR's operating cash flow was $0 while its capital expenditure stood at $19.11 billion.
Comparatively, Terumo Corp ADR paid $0.33 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Terumo Corp ADR stock is currently trading at $29.24 per share. It touched a 52-week high of $33.66 and a 52-week low of $33.66. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $30.39 and 200-day moving average was $29.33 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0.5% are held by institutions.
Frequently Asked Questions About Terumo Corp ADR
Similar Industry Stocks (Medical Instruments & Supplies)
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.